Results 11 to 20 of about 7,531 (200)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

npj Vaccines, 2022
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination ...
Johannes B. Goll, Aarti Jain, Travis L. Jensen, Rafael Assis, Rie Nakajima, Algis Jasinskas, Lynda Coughlan, Sami R. Cherikh, Casey E. Gelber, S. Khan, D. Huw Davies, Philip Meade, Daniel Stadlbauer, Shirin Strohmeier, Florian Krammer, Wilbur H. Chen, Philip L. Felgner   +16 more
doaj   +5 more sources

Immunology and efficacy of MF59-adjuvanted vaccines [PDF]

Human Vaccines & Immunotherapeutics, 2018
Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries.
Eun-Ju Ko, Sang-Moo Kang
doaj   +3 more sources

AS03- and MF59-Adjuvanted Influenza Vaccines in Children [PDF]

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Bali Pulendran, Bali Pulendran, Bali Pulendran, Claire-Anne Siegrist, Andrew J. Pollard   +9 more
doaj   +4 more sources

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children [PDF]

International Journal of Infectious Diseases, 2019
Objective: To demonstrate the potential of an MF59-adjuvanted inactivated trivalent seasonal influenza vaccine (aIIV3; Fluad™) to improve the immune response in young children, we review the immunogenicity, efficacy, and safety/tolerability of aIIV3 from
Sanjay S. Patel, Svetlana Bizjajeva, Kelly Lindert, Esther Heijnen, Janine Oberye   +4 more
doaj   +3 more sources

A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance [PDF]

, 2016
The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2016.00162BACKGROUND: A vaccine for Chlamydia trachomatis is of urgent medical need.
Badamchi-Zadeh, A, Barinaga, G, Follman, F, Gomes, JP, Korber, BT, McKay, PF, Nunes, A, Shattock, RJ, Tregoning, JS, Walters, AA   +9 more
core   +8 more sources

Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review [PDF]

, 2020
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatological condition affecting individuals aged >50 years. There have been rare reports of PMR and other vasculitides developing within 3 months of influenza vaccination.
Bassendine, Margaret F., Bridge, Simon
core   +1 more source

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. [PDF]

PLoS ONE, 2014
In an open label clinical study (2007), MF59-adjuvanted hemagglutinin (HA) vaccine from H5N1-A/Vietnam/1194/2004 (clade 1) was administered to subjects previously vaccinated (primed) with clade 0 H5N3 (A/duck/Singapore/97) vaccine at least 6 years ...
Surender Khurana, Elizabeth M Coyle, Milena Dimitrova, Flora Castellino, Karl Nicholson, Giuseppe Del Giudice, Hana Golding   +6 more
doaj   +1 more source

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine [PDF]

New England Journal of Medicine, 2009
The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority.We conducted a single-center study, involving 176 adults, 18 to 50 years of age, to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted ...
Clark, Tristan, Pareek, Manish, Höschler, Katja, Dillon, Helen, Nicholson, Karl G, Groth, Nicola, Stephenson, Iain   +6 more
openaire   +4 more sources

Rational Development of a Novel Emulgel Adjuvant for Single-Shot Effective Vaccination: A Multivariate Analysis Approach. [PDF]

Adv Mater
Using multivariate analysis, a novel emulgel adjuvant is developed by combining key nanoemulsion formulation variables–hydrogel trapping, small globule size, and mannide monooleate surfactant–achieving 10× greater immunogenicity than MF59 in mice after a single shot.
Shalash AO, Hussein WM, Nahar UJ, Wang J, Lu L, Azuar A, Kiong JJE, Koirala P, Khalil ZG, Toth I.   +9 more
europepmc   +2 more sources

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age [PDF]

, 2014
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in children, because they are at greater risk of disease than adults.
Abarca, Katia, Arora, Ashwani, Della Cioppa, Giovanni, Kieninger-Baum, Dorothee, Knuf, Markus, Lattanzi, Maria, Leroux-Roels, Geert, Pedotti, Paola, Rivera, Luis, Rümke, Hans C   +9 more
core   +2 more sources